For new technologies to gain adoption in pharma, the central value proposition must be about de-risking decisions. Leaders and regulators often view the technology as a "black box" and are less concerned with its mechanics than with its ability to give them confidence in making safer, more reliable choices.

Liz Parrish pushes back against claims that her work is reckless or too fast. She contends her team moves too slowly, spending years studying each therapy. Their pace only appears rapid in comparison to the extremely slow processes of mainstream medical research and regulation.

Drug developers often operate under a hyper-conservative perception of FDA requirements, avoiding novel approaches even when regulators might encourage them. This anticipatory compliance, driven by risk aversion, becomes a greater constraint than the regulations themselves, slowing down innovation and increasing costs.

Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

While patents are important, a pharmaceutical giant's most durable competitive advantage is its ability to navigate complex global regulatory systems. This 'regulatory know-how' is a massive barrier to entry that startups cannot easily replicate, forcing them into acquisition by incumbents.

The biggest competitor for a new technology in pharma quality control isn't another new technology, but established methods. The industry is highly change-averse due to regulatory risk, so any innovation must offer a value proposition that is orders of magnitude better, not just incremental, to overcome this inertia.

While critical, compliance is frequently weaponized as an unchallengeable reason to reject innovation or collaboration between commercial and medical affairs. It's an easy way to shut down conversations about change when the real barrier is a lack of will to evolve.

Founders pitching pharma must determine if their solution is being 'pulled' by a stated R&D priority or 'pushed' by an enthusiastic innovation scout. A 'pull' signifies a fast-track deal process, while a 'push' could mean a multi-year educational journey before any deal is possible.

When seeking FDA compliance, the founders found that established consultants lacked experience in their 'untouched' niche. They ended up paying experts to learn the industry alongside them, showing that true disruption requires founders to become the ultimate authority, even over their paid advisors.